Dyne Therapeutics, Inc. (NASDAQ:DYN) Major Shareholder Venture Fund Xi L.P. Atlas Sells 201,095 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYNGet Free Report) major shareholder Venture Fund Xi L.P. Atlas sold 201,095 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $23.72, for a total value of $4,769,973.40. Following the sale, the insider now directly owns 6,151,467 shares of the company’s stock, valued at approximately $145,912,797.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Venture Fund Xi L.P. Atlas also recently made the following trade(s):

  • On Wednesday, February 28th, Venture Fund Xi L.P. Atlas sold 154,674 shares of Dyne Therapeutics stock. The shares were sold at an average price of $24.84, for a total value of $3,842,102.16.
  • On Friday, February 23rd, Venture Fund Xi L.P. Atlas sold 159,542 shares of Dyne Therapeutics stock. The shares were sold at an average price of $22.70, for a total value of $3,621,603.40.
  • On Wednesday, February 21st, Venture Fund Xi L.P. Atlas sold 184,501 shares of Dyne Therapeutics stock. The shares were sold at an average price of $22.57, for a total value of $4,164,187.57.
  • On Friday, February 16th, Venture Fund Xi L.P. Atlas sold 162,707 shares of Dyne Therapeutics stock. The stock was sold at an average price of $23.14, for a total value of $3,765,039.98.

Dyne Therapeutics Price Performance

NASDAQ DYN traded up $0.38 on Wednesday, hitting $24.98. 1,756,961 shares of the company’s stock were exchanged, compared to its average volume of 2,515,651. The firm’s 50-day moving average price is $19.02 and its two-hundred day moving average price is $13.05. Dyne Therapeutics, Inc. has a fifty-two week low of $6.40 and a fifty-two week high of $25.50. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -6.96 and a beta of 0.87.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Raymond James lifted their price target on Dyne Therapeutics from $27.00 to $56.00 and gave the stock a “strong-buy” rating in a report on Thursday, January 4th. HC Wainwright assumed coverage on Dyne Therapeutics in a report on Tuesday, February 20th. They issued a “buy” rating and a $36.00 target price for the company. Finally, StockNews.com raised Dyne Therapeutics to a “sell” rating in a report on Thursday, December 21st. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $33.50.

Check Out Our Latest Report on Dyne Therapeutics

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. VR Adviser LLC purchased a new position in shares of Dyne Therapeutics during the 2nd quarter worth $24,457,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Dyne Therapeutics in the 4th quarter worth $15,758,000. State Street Corp raised its position in shares of Dyne Therapeutics by 196.2% in the 2nd quarter. State Street Corp now owns 1,779,740 shares of the company’s stock worth $20,022,000 after buying an additional 1,178,928 shares during the period. Commodore Capital LP purchased a new position in shares of Dyne Therapeutics in the 4th quarter worth $11,970,000. Finally, BlackRock Inc. raised its position in shares of Dyne Therapeutics by 26.8% in the 2nd quarter. BlackRock Inc. now owns 3,322,187 shares of the company’s stock worth $37,375,000 after buying an additional 702,966 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

(Get Free Report)

Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Further Reading

Insider Buying and Selling by Quarter for Dyne Therapeutics (NASDAQ:DYN)

Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.